124 related articles for article (PubMed ID: 10423925)
21. Corpuscular thymoma: entity or variant of organotypical thymomas WHO B2/B3?
Laeng RH; Eimoto T; Kuo TT; Zettl A; Marx A; Moschopulos M; Tateyama H; Shimokawa K
Pathol Res Pract; 2006; 202(10):697-704. PubMed ID: 16887284
[TBL] [Abstract][Full Text] [Related]
22. Thymic epithelial cells of human patients affected by myasthenia gravis overexpress IGF-I immunoreactivity.
Marinova TT; Kuerten S; Petrov DB; Angelov DN
APMIS; 2008 Jan; 116(1):50-8. PubMed ID: 18254780
[TBL] [Abstract][Full Text] [Related]
23. Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patients.
Saito R; Onodera H; Tago H; Suzuki Y; Shimizu M; Matsumura Y; Kondo T; Itoyama Y
J Neuroimmunol; 2005 Dec; 170(1-2):172-8. PubMed ID: 16214223
[TBL] [Abstract][Full Text] [Related]
24. Primary cultures of human myasthenia gravis thymus and normal thymus. Studies of cell morphology, cell proliferative pattern and localization of alpha-bungarotoxin binding sites on cultured thymic cells.
Matsumoto Y; Furuya A; Kobayashi T; Tsukagoshi H
J Neurol Sci; 1986 Sep; 75(2):121-33. PubMed ID: 3760907
[TBL] [Abstract][Full Text] [Related]
25. Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology.
Moser B; Janik S; Schiefer AI; Müllauer L; Bekos C; Scharrer A; Mildner M; Rényi-Vámos F; Klepetko W; Ankersmit HJ
PLoS One; 2014; 9(4):e94118. PubMed ID: 24705787
[TBL] [Abstract][Full Text] [Related]
26. Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution.
Bernasconi P; Barberis M; Baggi F; Passerini L; Cannone M; Arnoldi E; Novellino L; Cornelio F; Mantegazza R
Am J Pathol; 2005 Jul; 167(1):129-39. PubMed ID: 15972959
[TBL] [Abstract][Full Text] [Related]
27. Isolation and functional characterization of anti-acetylcholine receptor subunit-specific autoantibodies from myasthenic patients: receptor loss in cell culture.
Sideris S; Lagoumintzis G; Kordas G; Kostelidou K; Sotiriadis A; Poulas K; Tzartos SJ
J Neuroimmunol; 2007 Sep; 189(1-2):111-7. PubMed ID: 17617475
[TBL] [Abstract][Full Text] [Related]
28. [Fas antigen gene in thymuses from patients with myasthenia gravis].
Utsugisawa K; Yamagata M; Saitoh K; Kawamorita A; Tohgi H
Rinsho Shinkeigaku; 1995 Feb; 35(2):121-5. PubMed ID: 7540122
[TBL] [Abstract][Full Text] [Related]
29. Regulatory and pathogenic mechanisms in human autoimmune myasthenia gravis.
Le Panse R; Cizeron-Clairac G; Cuvelier M; Truffault F; Bismuth J; Nancy P; De Rosbo NK; Berrih-Aknin S
Ann N Y Acad Sci; 2008; 1132():135-42. PubMed ID: 18567863
[TBL] [Abstract][Full Text] [Related]
30. Immunocytochemical localization of thymosin-alpha 1 in thymic epithelial cells of normal and myasthenia gravis patients and in thymic cultures.
Dalakas MC; Engel WK; McClure JE; Goldstein AL; Askanas V
J Neurol Sci; 1981 May; 50(2):239-47. PubMed ID: 7014787
[TBL] [Abstract][Full Text] [Related]
31. BDNF and its receptors in human myasthenic thymus: implications for cell fate in thymic pathology.
Berzi A; Ayata CK; Cavalcante P; Falcone C; Candiago E; Motta T; Bernasconi P; Hohlfeld R; Mantegazza R; Meinl E; Farina C
J Neuroimmunol; 2008 Jul; 197(2):128-39. PubMed ID: 18555538
[TBL] [Abstract][Full Text] [Related]
32. Altered expression of Th1-type chemokine receptor CXCR3 on CD4+ T cells in myasthenia gravis patients.
Suzuki Y; Onodera H; Tago H; Saito R; Ohuchi M; Shimizu M; Matsumura Y; Kondo T; Yoshie O; Itoyama Y
J Neuroimmunol; 2006 Mar; 172(1-2):166-74. PubMed ID: 16427705
[TBL] [Abstract][Full Text] [Related]
33. Autoimmunizing mechanisms in thymoma and thymus.
Willcox N; Leite MI; Kadota Y; Jones M; Meager A; Subrahmanyam P; Dasgupta B; Morgan BP; Vincent A
Ann N Y Acad Sci; 2008; 1132():163-73. PubMed ID: 18567866
[TBL] [Abstract][Full Text] [Related]
34. The role of apoptosis in normal ontogenesis and solid human neoplasms.
Kaiser HE; Bodey B
In Vivo; 2000; 14(6):789-803. PubMed ID: 11204498
[TBL] [Abstract][Full Text] [Related]
35. Mesangial proliferative glomerulonephritis with deposits of anti-nicotinic acetylcholine receptor antibody in a patient with myasthenia gravis.
Mitsui T; Okada K; Kuhara T; Hashizume T; Okazaki S; Kawajiri M; Matsumoto T
J Clin Neurosci; 2001 Sep; 8(5):454-6. PubMed ID: 11535018
[TBL] [Abstract][Full Text] [Related]
36. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients.
Melms A; Schalke BC; Kirchner T; Müller-Hermelink HK; Albert E; Wekerle H
J Clin Invest; 1988 Mar; 81(3):902-8. PubMed ID: 2449461
[TBL] [Abstract][Full Text] [Related]
37. Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor.
Maggi L; Andreetta F; Antozzi C; Confalonieri P; Cornelio F; Scaioli V; Mantegazza R
Neuromuscul Disord; 2008 Aug; 18(8):678-80. PubMed ID: 18657424
[TBL] [Abstract][Full Text] [Related]
38. Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis.
Cavalcante P; Barberis M; Cannone M; Baggi F; Antozzi C; Maggi L; Cornelio F; Barbi M; Didò P; Berrih-Aknin S; Mantegazza R; Bernasconi P
Neurology; 2010 Apr; 74(14):1118-26. PubMed ID: 20368632
[TBL] [Abstract][Full Text] [Related]
39. Phenotypic changes of the subseptal thymic epithelium in myasthenia gravis.
Savino W; Takacs L; Monostori E; Dardenne M
Thymus; 1988-1989; 12(2):111-6. PubMed ID: 2471300
[TBL] [Abstract][Full Text] [Related]
40. Expression of OX40 and OX40 ligand (gp34) in the normal and myasthenic thymus.
Onodera J; Nagata T; Fujihara K; Ohuchi M; Ishii N; Sugamura K; Itoyama Y
Acta Neurol Scand; 2000 Oct; 102(4):236-43. PubMed ID: 11071109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
